A research study centered on magic mushrooms in Canada revealed that nearly 80% of participants believe that psilocybin should be medically accessible to distressed patients. Additionally, about two-thirds of the Canadian survey respondents agreed that psilocybin should be legally available to those in need.
Besides advocating for increased availability, a notable 84.8 percent of participants think that the public health system should bear the costs of such treatments. A majority of Canadians view psilocybin as a promising option, especially for alleviating end-of-life distress.
[toc]
Key Insights:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a credible medical alternative for managing end-of-life existential distress.
- Magic mushrooms are deemed safe for the treatment of existential distress.
- Participants in two double-blind trials reported immediate and lasting benefits, with effects persisting over six months or even longer.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. It can trigger feelings of helplessness, isolation, anxiety, and a sense of lost meaning and purpose. This form of distress is particularly prevalent among patients with life-threatening illnesses, potentially leading to thoughts of hastening death or contemplating suicide.
Often, those facing terminal illnesses or substantial life changes are the most prone to this kind of distress. It significantly impacts their mental health and overall quality of life.
Existential therapy aims to tackle issues like anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. This therapy may involve numerous sessions and might not be successful for everyone.
The uncertainty about the effectiveness of such therapy is a primary reason why many individuals seek alternative treatments.
The Stance of Health Canada on Psilocybin as a Therapeutic Option
In the last two decades, preliminary clinical trials have emphasized the potential advantages of psychedelic substances in addressing complex mental disorders. Notably, psilocybin has been proven to provide quick and long-lasting relief from existential distress in patients who are in the terminal phase of their lives.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially in cases where conventional treatments are ineffective, Health Canada revised the Special Access Program in 2022. This revision enables healthcare practitioners to apply for controlled substances on behalf of their patients.
Canadian Advocacy for Psilocybin Accessibility
A research published in the Palliative Care Journal evaluates societal views on psilocybin-aided therapy for end-of-life care. The research data includes:
| Methodology | Engagement from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia, 19% of whom had previous experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-aided therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% believe psilocybin should be integrated into medical treatment. 84.8% endorse the public health system’s delivery of this therapy. 44.2% are of the opinion that healthcare professionals should administer the substance without the oversight of Health Canada. |
These findings align with surveys conducted in Canada, England, and Australia. The researchers highlighted that their study is distinctive as it focuses on the use of psychoactive substances to mitigate existential distress in end-of-life situations.
Rationale for Canadian Endorsement of Psilocybin Application
An increasing number of Canadians are supporting the utilization of psilocybin for treatment, largely driven by evidence from esteemed research institutions. Another influencing factor is the perceived safety of psilocybin mushrooms in relieving existential distress. There have been no reports of severe adverse health effects, such as multi-organ failure, across various studies.
| Study | Method | Results |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and sustained |
| The duration of the benefits can extend to six months or even longer. The efficacy of the therapy is largely due to mystical experiences that are characterized by a profound sense of unity and deep emotional insights. | ||
| Trial at New York University | 29 patients were randomly chosen to receive either psilocybin or the active placebo niacin. | The results were consistent with those of the Johns Hopkins study. Those participants who received psilocybin reported psychological relief, and an enhanced understanding of life and death. |
| BMC Palliative Care | Nineteen participants, which included 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The objective of the study was to comprehend how palliative care professionals perceive existential distress and their viewpoint on psychedelic therapy as a treatment choice. | Palliative care practitioners indicated that psychedelic-assisted therapy (PAT) may have the potential to alleviate existential distress. |
Patient Experiences
Besides scientific studies, numerous patient narratives also support the effectiveness of psilocybin in boosting mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares a life-altering experience during her assisted therapy. She visualizes being on a raft, surrounded by nature, and accompanied by whimsical creatures. This vision imbues in her a profound realization of the universe’s interconnectedness and support, providing her with immense peace and affirmation.
Despite availing traditional mental health support, Yokoi still suffered from severe anxiety and distress post her diagnosis. Psilocybin therapy helped her reestablish a connection with her body and gave her a tangible sense of love and support. This significantly improved her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was an administrative supervisor in healthcare working full-time when the study was carried out and identified herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy reported significant decreases in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked about any alterations in her religious or spiritual beliefs post her therapy session, she stated that the experiences had infused her beliefs with meaning and reality.
Brenda’s Encounter
Brenda, a 60-year-old woman, was diagnosed with stage I colon cancer. She had never consumed hallucinogens before, as identified during screening, and was found to have Chronic Adjustment Disorder with concomitant Anxiety.
During therapy, Brenda experienced the sensation of death twice. She came out of the sessions with a newfound perspective on death, seeing it as an integral part of life’s journey. She credited the study as the catalyst for her recovery from childhood trauma. The data collected reflected her profound transformation.
Increased spirituality, coupled with diminished anxiety and death apprehension, were observed.
Assortment of Magic Mushroom Products in Canada
At present, restrictions may apply to the accessibility of psilocybin capsules and other products designed to alleviate existential distress or treat mental health disorders. However, trustworthy online dispensaries serve as a viable source for such products when needed.
| Characteristic | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and other South American countries nearby. | Discovered in Cambodia, near the Angkor Wat Temple. | Associated with Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderate potency; ideal for beginners. | Moderate potency as well; perfect for newcomers. | Highly potent; suitable for those with intermediate to advanced experience. |
| Effects | Causes a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Triggers an energizing and long-lasting high, minor visual alterations, increased creativity, euphoria, a smooth physical high, fractal images, and feelings of joy. | Induces profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, focus, social awareness, and mood uplift. |
Using Psilocybin Products to Alleviate End-of-life Discomfort
Many patients experience significant existential or end-of-life distress as they approach the end of their life. Conventional treatments for this distress may not always be effective, leading to increased support in Canada for easier access to magic mushrooms within the public healthcare system. This growing public interest could
We urge regulatory authorities to recognize the potential of magic mushrooms as a legitimate treatment option. Get your psychedelics and shroom delivery from Shrooms Online Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Experiences of Psychedelic-assisted therapy (PAT) can vastly differ among patients. Meticulous preparation and compliance with specific protocols are crucial for a successful outcome. Patients are required to complete a comprehensive screening and mental readiness assessment prior to substance intake.
- Prior to the Session: Patients undergo a thorough evaluation. The therapist discusses the patient’s goals and expectations to set the session’s intentions. The therapist also outlines the potential effects of the process and what the patient can expect during the session.
- The Session: Patients receive a regulated dosage of the substance in a serene, undisturbed environment to facilitate relaxation and self-reflection. The therapist offers ongoing support and guidance throughout this process.
- Post-Session Integration Therapy: This therapy helps patients interpret and assimilate their experiences. Follow-up sessions provide continuous support and counselling to enhance the insights and transformations achieved during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, predominantly the 5-HT2A receptor. This interaction can cause alterations in perception, mood, and cognition, leading to profound shifts in consciousness, emotional epiphanies, and new viewpoints.
Is psilocybin therapy available to all?
Psilocybin therapy isn’t universally appropriate. Patients with certain mental health conditions or existential distress are carefully screened to exclude those with a past history of psychosis.
Related Articles:
